This guide addresses a real and ongoing dosing safety issue affecting people who use compounded GLP-1 medications. If your pharmacy recently sent you a new vial and did not tell you whether the concentration changed, you may be taking a different dose in milligrams than you intended, even if you are drawing the same number of units. This is not a hypothetical concern. It is being reported in active GLP-1 patient communities in June 2026. Read this guide before your next injection. Then call your pharmacy and confirm the concentration on your current vial.
Why Compounded GLP-1 Dosing Is Different
Moderate — Compounding pharmacy regulatory framework; FDA 503A/503B guidance; documented dosing variability in compounded injectablesCompounded GLP-1 medications are not standardized the way pharmaceutical products are. When you receive brand-name Wegovy or Zepbound, you are getting a pre-filled, single-dose pen calibrated by the manufacturer to deliver a precise amount of active drug with each injection. The dose in milligrams is fixed, the delivery mechanism is engineered, and there is no unit conversion required. You dial the pen, you inject, and the math has already been done for you.
Compounded semaglutide and tirzepatide work entirely differently. Compounding pharmacies mix these medications in-house, filling multi-dose vials with a solution of their chosen concentration. That concentration — how many milligrams of active drug are dissolved per milliliter of solution — is set by the pharmacy and can vary from one pharmacy to another, and from one batch to the next at the same pharmacy. Two patients prescribed the identical "0.25mg weekly semaglutide" dose may receive vials from different compounders with entirely different concentrations, and they will be instructed to draw entirely different numbers of units to deliver that same milligram dose.
This creates a dosing math problem that falls entirely on the patient to solve. The pharmacy gives you instructions, but those instructions are only correct for the specific concentration in that specific vial. If the concentration changes — whether the pharmacy told you or not, whether your instructions sheet was updated or not — the unit volume you draw must change accordingly. There is no pre-filled pen here to absorb that calculation. The math is yours to verify.
Compounded semaglutide and tirzepatide are prescription medications. They require a valid prescription from a licensed healthcare provider. Nothing in this guide is a substitute for that prescribing relationship, and all dose decisions must be made in consultation with your prescribing provider. This guide is designed to help you understand the information on your label and have an informed conversation with your pharmacy and provider — not to enable independent dosing decisions.
The regulatory context makes this more complicated, not less. Compounding pharmacies that operate under FDA 503A authority (traditional compounders serving individual patients) are regulated primarily at the state level, with variable standards for labeling, quality testing, and concentration verification. 503B outsourcing facilities operate under stricter federal standards but still produce individualized vials rather than the standardized unit doses of commercial pharmaceutical products. Neither category guarantees that your new vial from the same pharmacy will have the same concentration as your previous vial, or that you will be proactively notified when it changes.
That structural gap — between the standardization patients may reasonably expect and the variability that actually exists in compounded medications — is why this guide exists. The issue described in r/glp1 this week is not an isolated incident. It is a predictable consequence of how compounded injectable medications work when patients are not given the tools to verify what they are receiving.
Section 2 — Label ReadingHow to Read Your Concentration Label
Moderate — Standard pharmaceutical labeling requirements; FDA compounding guidanceYour compounded GLP-1 vial label should contain specific information that allows you to calculate your actual dose. Not every compounding pharmacy labels with the same level of detail, and the absence of key information is itself a warning sign. Here is what a proper label should include, and how to read it.
What a Proper Compounded GLP-1 Label Should Include
A properly labeled compounded GLP-1 vial should state all of the following:
- Drug name and any added ingredients: For example, "Semaglutide" or "Semaglutide with B12." Some compounders add vitamin B12 or other compounds; this affects the label but not the semaglutide concentration calculation.
- Concentration in mg/ml: This is the most critical number on the label. It tells you how many milligrams of active drug are present in each milliliter of solution. Example: "5 mg/ml" or "7.5 mg/ml." If this number is absent, you cannot calculate your dose.
- Total volume of the vial in ml: This tells you how much solution is in the vial. Example: "2 ml vial." Combined with the concentration, this tells you the total amount of drug. A 5 mg/ml concentration in a 2 ml vial contains 10 mg total.
- Total drug content in mg: Some labels also state the total, such as "10 mg total." This is a useful cross-check: total mg should equal concentration times volume.
- Lot number or batch number: This allows the pharmacy to track the specific production batch if there is a quality concern or recall. Absence of a lot number is a red flag.
- Beyond-use date: Compounded medications have expiration dates based on stability data, not manufacturer shelf-life testing. This date tells you when to discard the vial.
- Pharmacy name and contact information: You should be able to identify which pharmacy prepared the vial and how to contact them with questions.
Label reads: "Semaglutide 5 mg/ml, 2 ml" — This means the solution contains 5 milligrams of semaglutide per milliliter, and the vial contains 2 milliliters total. Total semaglutide content: 5 mg/ml × 2 ml = 10 mg total. To deliver 0.25 mg, you need to draw 0.05 ml — which on a U-100 insulin syringe is 5 units.
Label reads: "Semaglutide 7.5 mg/ml, 2 ml" — This means the solution contains 7.5 mg per ml. Total content: 15 mg. To deliver the same 0.25 mg dose, you need approximately 0.033 ml — which on a U-100 syringe is approximately 3.3 units.
The practical implication is that the same prescribed milligram dose requires drawing a different number of units depending on which concentration your pharmacy used. This is the number that must be recalculated every time you start a new vial if there is any possibility the concentration has changed.
How Insulin Syringes Measure Volume
Compounded injectable GLP-1 medications are typically administered using U-100 insulin syringes. These syringes are marked in "units," where 100 units equals 1 milliliter. This is the universal standard for insulin syringes sold in the United States. A U-100 syringe divides each milliliter of volume into 100 equal increments called units. So 1 unit on a U-100 syringe equals 0.01 milliliters. Ten units equals 0.1 ml. Fifty units equals 0.5 ml.
The critical insight is that the syringe measures volume, not mass. When your pharmacy says "draw 10 units," they mean draw 0.1 ml of solution. How many milligrams of drug that 0.1 ml delivers depends entirely on the concentration of the solution in your vial. Change the concentration, and 10 units delivers a different amount in milligrams, even though the volume is identical.
Units to Milligrams: The Conversion
Strong — Basic pharmaceutical dosing math; unit-to-volume conversion is standardized for U-100 syringesThis is the calculation that every patient using compounded injectable GLP-1 medications should know how to perform. It is not complicated, but it requires knowing the concentration on your current vial.
(Units drawn ÷ 100) × Concentration (mg/ml) = Dose in mg
Example A: 5 units drawn, concentration 5 mg/ml → (5 ÷ 100) × 5 = 0.25 mg
Example B: 5 units drawn, concentration 7.5 mg/ml → (5 ÷ 100) × 7.5 = 0.375 mg
Example C: 10 units drawn, concentration 5 mg/ml → (10 ÷ 100) × 5 = 0.5 mg
Example D: 10 units drawn, concentration 7.5 mg/ml → (10 ÷ 100) × 7.5 = 0.75 mg
Example A and Example B illustrate the danger described in this week's patient safety reports. A patient drawing 5 units who was previously receiving a 5 mg/ml vial was getting 0.25 mg per injection. If their pharmacy silently changed the concentration to 7.5 mg/ml and kept the same "draw 5 units" instruction, that patient is now receiving 0.375 mg per injection — a 50% dose increase from the same physical injection volume, with no visible change in how the syringe looks when loaded.
To reverse the formula — that is, to calculate how many units to draw to deliver a prescribed milligram dose from a known concentration — the calculation is:
Units to draw = (Prescribed dose in mg ÷ Concentration in mg/ml) × 100
Example: Prescribed 0.5 mg, concentration 5 mg/ml → (0.5 ÷ 5) × 100 = 10 units
Example: Prescribed 0.5 mg, concentration 7.5 mg/ml → (0.5 ÷ 7.5) × 100 = 6.67 units
Example: Prescribed 0.25 mg, concentration 5 mg/ml → (0.25 ÷ 5) × 100 = 5 units
Example: Prescribed 0.25 mg, concentration 7.5 mg/ml → (0.25 ÷ 7.5) × 100 = 3.33 units
Recalculate your unit volume whenever you start a new vial from any compounding pharmacy. Do not assume that the new vial has the same concentration as the previous one, even if the same pharmacy sent it. Batch-to-batch concentration changes are a known feature of the compounding supply chain. The calculation takes 30 seconds. Confirm the concentration with your pharmacy, run the math, and verify it matches your prescriber's instructions.
These calculations apply equally to tirzepatide and any other compounded GLP-1 or GIP/GLP-1 medication delivered by subcutaneous injection. The drug names change; the math does not. Whenever volume is measured in units and dose is prescribed in milligrams, the concentration is the bridge between those two values, and it must be confirmed for every new vial.
Section 4 — The Current CrisisThe Concentration Change Problem
Preliminary — Patient-reported; community surveillance; no published clinical data yet on prevalenceThe patient safety concern that prompted this guide is a specific scenario being actively reported in June 2026 in GLP-1 patient communities including r/glp1: a compounding pharmacy changed semaglutide concentration from 7.5 mg/ml to 5.0 mg/ml but kept the same unit instructions. Patients who were drawing 10 units at 7.5 mg/ml were receiving 0.75 mg per injection. After receiving a new vial at 5.0 mg/ml with the same "draw 10 units" instruction, those same patients are now receiving 0.5 mg per injection — a 33% dose reduction they were not told about.
This is not an edge case. Compounding pharmacies adjust their formulations for various reasons: drug acquisition costs, concentration stability at higher formulations, batch consistency, supply chain availability, and regulatory guidance changes. The FDA has issued guidance affecting compounded semaglutide availability multiple times in 2024 through 2026, creating pressure on pharmacies to reformulate. Each reformulation is an opportunity for a concentration change that, if not communicated to patients with updated dosing instructions, creates the exact problem described above.
The problem is compounded — in both senses of the word — by the structure of telehealth-to-compounding-pharmacy pipelines. Many patients receive their GLP-1 medications through telehealth platforms that prescribe and then route to a network compounding pharmacy. Communication about formulation changes does not always flow cleanly from pharmacy to telehealth platform to patient. A patient may receive a new vial at a different concentration with instructions that were generated for the old concentration, and no one in the chain may have flagged the discrepancy.
The two failure modes have different consequences. An unrecognized dose reduction (same units, lower concentration) is frustrating and can be mistaken for medication tolerance or inefficacy — but it is generally not acutely dangerous. An unrecognized dose increase (same units, higher concentration) carries acute safety risk: intensified nausea and vomiting, potential dehydration, and in the most severe cases, serious adverse effects that may require medical attention. If you have started a new vial and feel significantly more side effects than you expected, a concentration change in the direction of higher is a plausible explanation that should be investigated before your next dose.
Asking your pharmacy directly whether the concentration has changed between batches takes one phone call or message. Most pharmacies will tell you. Some may not have a clear communication protocol for notifying patients proactively — which is a systemic problem in the compounding pharmacy space, but one that you can work around by asking the question yourself. The question is: "Has the concentration in mg/ml changed in this batch compared to my previous batch?" That question, asked every time you receive a new vial, is the simplest possible safeguard against this specific failure mode.
A related worry surfaces when a new vial comes with instructions to draw more units than before (for example, 11 units jumping to 22). That can mean one of two very different things, and you must confirm which: either the concentration was lowered, so the larger volume delivers the same milligram dose — or it is a genuine dose increase. Those are not interchangeable, and only your prescriber or pharmacy can tell you which applies to your vial. As for the fear of “injecting carrier fluid instead of medicine”: a more dilute vial does mean more bacteriostatic water per injection, but that carrier is inert and normal — you are still getting your full prescribed milligrams as long as the unit-to-concentration math is correct. The danger is never the carrier volume; it is an unrecognized change in the actual milligram dose. Confirm the milligrams, not just the units.
Red Flags on Your Label
Moderate — FDA compounding labeling requirements; patient safety reporting patternsNot all compounding pharmacies label with the same level of clarity, and the absence of certain information is itself a safety signal. Here are the specific red flags to look for when you receive a compounded GLP-1 vial.
- The label does not state the concentration in mg/ml. Without this number, you cannot verify your dose. A label that shows only the drug name and a unit instruction is incomplete.
- Your dosing instructions say "draw X units" without specifying the resulting dose in milligrams. Proper instructions should specify both: "Draw X units to deliver Y mg."
- No batch number or lot number appears on the vial or accompanying paperwork. Lot numbers are required for traceable compounding quality assurance. Their absence suggests inadequate quality documentation.
- No pharmacy name, address, or contact information appears on the label. You should always be able to identify who compounded your medication and how to reach them.
- Your dosing instructions did not change despite the pharmacy indicating (or you noticing) that the vial looks different, has a different volume, or arrived with different paperwork from usual. Changed presentation with unchanged instructions is a red flag for a concentration change without instruction update.
- The vial appearance, color, or consistency differs from previous batches. Legitimate batch-to-batch variation exists, but unexplained visual changes are worth querying with the pharmacy.
- The beyond-use date appears altered, handwritten over a printed date, or is unusually distant. Stability dating for compounded semaglutide and tirzepatide should follow established guidelines; unusually long dates may indicate documentation problems.
- Instructions arrived separately from the vial, on a sheet that does not reference the specific batch or concentration. Generic instruction sheets may not account for batch-specific concentration differences.
If you identify any of these red flags, the appropriate response is to pause — do not inject until you have spoken with either your pharmacy or your prescribing provider and confirmed the concentration on your specific current vial and the correct unit volume to draw. Delaying a single weekly injection by a day or two while you verify information carries no meaningful clinical consequence. Injecting an unverified dose from a vial with a labeling problem carries a real one.
Before discarding any compounded GLP-1 vial, photograph the label with your phone. This takes five seconds and gives you a permanent record of the concentration, lot number, and instructions for that specific batch. If a problem arises later — an apparent change in medication response, a dose discrepancy, or a pharmacy quality inquiry — having the historical label data is invaluable. Keep the photos in a designated album on your phone associated with your GLP-1 medication.
It is also worth scrutinizing what your telehealth platform or prescribing provider sends you. Some telehealth GLP-1 providers include dosing titration schedules and unit instructions in their patient portal or app. If those instructions were generated before a pharmacy reformulation, they may be stale. The authoritative source for your unit dosing instructions is the pharmacy that produced your current vial, not a generic schedule generated at the time of prescription. When in doubt, confirm directly with the compounder.
Section 6 — Action StepsVerifying Your Dose: A Step-by-Step Process
Moderate — Standard pharmaceutical patient safety practices; compounding verification protocolsDose verification for compounded injectable medications is not something your pharmacy does for you automatically. It is a process you need to own and execute for every new vial. Here is how to do it.
- Step 1: Read the concentration off your current vial. Find the mg/ml number on the label. This is the concentration. Write it down. If it is not on the label, call your pharmacy before proceeding.
- Step 2: Do the math. Apply the formula: (Units you plan to draw ÷ 100) × Concentration in mg/ml = Dose in milligrams. Compare the result to your prescribed milligram dose.
- Step 3: Compare to your prescribed dose. Your prescriber wrote an order in milligrams. Does your calculation match? If you are not sure what milligram dose was prescribed, that is a question for your provider — not something to estimate.
- Step 4: Call your pharmacy if they do not match. Do not adjust your unit draw on your own. If your calculation shows a mismatch between the unit instruction and the milligram dose, contact your pharmacy and ask them to confirm the correct unit volume for your prescribed dose from this specific concentration vial.
- Step 5: Contact your prescriber if the pharmacy cannot resolve it. If your pharmacy is unresponsive, unclear, or if you believe the vial they sent does not match your prescription, your prescribing provider is the escalation path. Do not continue dosing from a vial you cannot verify.
- Step 6: Save your label photos. Before discarding the empty vial, photograph the label. Note the concentration, lot number, and beyond-use date. Store the photo on your phone.
- Step 7: Ask the specific question. When contacting your pharmacy about any new batch, ask explicitly: "What is the concentration of this vial in mg/ml, and what volume in units gives me my prescribed dose?" Request this confirmation in writing — via secure portal message, email, or text — so you have a documented record.
This process may feel redundant for a medication you have been taking for months without incident. It is worth doing anyway. The reported concentration changes described in this guide happened without any change in the patient's experience of ordering, receiving, and beginning a new vial. The failure is invisible until it is not — until you are either under-dosed and plateauing, or over-dosed and experiencing a sudden recurrence of side effects you thought you had moved past.
Getting Written Confirmation from Your Pharmacy
The specific question to ask your compounding pharmacy is: "What is the concentration of this vial in mg/ml, and what volume in units should I draw to deliver my prescribed dose of [X] mg?" Getting this in writing provides you with both the answer and documentation if there is ever a dispute or quality inquiry later.
Most reputable compounding pharmacies will answer this question clearly and promptly. It is a routine pharmaceutical question. If your pharmacy is unwilling or unable to tell you the concentration of the medication they sent you, that is a serious red flag about the quality and reliability of that pharmacy, and it is information worth sharing with your prescribing provider.
If you communicate through a telehealth platform's portal, send the message through that portal so the prescriber is aware you asked. Some telehealth providers have their own pharmacy relationships and can escalate a labeling concern on your behalf. Others are pass-through platforms that connected you to a pharmacy and have limited ability to intervene. Know which type you are dealing with.
Keeping a Simple Dose Log
Patients who manage their own injections benefit from keeping a simple log: date of injection, lot number of the vial, concentration confirmed, units drawn, calculated dose in mg. This does not need to be elaborate — a note in your phone's notes app is sufficient. If you ever need to reconstruct your dosing history for a provider or report an adverse event, this log is the documentation you will wish you had kept. It also surfaces concentration changes immediately: if the concentration column changes between vials, you see it before you inject rather than after.
When to Contact Your Provider Immediately
Moderate — GLP-1 adverse event profiles; FDA MedWatch reporting patterns for compounded GLP-1sMost concentration-related dosing discrepancies are discovered before they cause serious harm, through the verification process described in this guide. But some patients will discover a discrepancy only after experiencing symptoms that suggest an unintended dose change. Here is when to act immediately rather than waiting for your next scheduled appointment.
Do not take your next dose until you have spoken with your prescriber or pharmacist if you experience any of the following after starting a new vial:
- Sudden onset of severe nausea, vomiting, or diarrhea that is significantly more intense than anything you experienced during initial titration
- Rapid and unexpected weight loss in the first week of a new vial, which may signal a significant unintended dose increase
- You believe, based on the calculation described in this guide, that you may have taken an incorrect dose — higher or lower than prescribed
- Your label does not state a concentration, or the concentration you can read does not match what you were told to expect
- The unit instructions provided do not produce your prescribed milligram dose when you run the math
- Your label does not match the prescription your provider wrote in terms of drug name, concentration, or total volume
- You experience symptoms consistent with a significant GLP-1 dose increase: severe gastroparesis symptoms, inability to keep fluids down, or symptoms that feel like an acute adverse drug reaction rather than the expected mild side effect profile
Contacting your provider in these situations is not an overreaction. GLP-1 medications are potent agents with dose-dependent side effect profiles. A 50% dose increase from an unrecognized concentration change is the kind of event that produces real symptoms. Your provider needs to know if you believe you may have taken more than your prescribed dose, both to advise on symptom management and to document the potential adverse event.
If you experienced severe vomiting after starting a new vial and you suspect a concentration increase caused an unintended dose increase, do not continue dosing from that vial until your provider confirms what the correct unit draw should be. The instinct to push through the side effects and continue — common in patients who are motivated to stay on GLP-1 therapy — is understandable, but it is the wrong call when the cause of the symptoms may be a dosing error rather than expected pharmacology.
Reporting to MedWatch and Your State Board of Pharmacy
If you believe a compounding pharmacy supplied you with a vial at a concentration different from what was labeled, or failed to update your dosing instructions when the concentration changed, you have reporting options beyond your prescriber. The FDA MedWatch voluntary reporting program accepts adverse event and medication error reports from patients at fda.gov/safety/medwatch. Your state board of pharmacy has jurisdiction over compounding pharmacies operating within the state and can receive complaints about labeling and quality failures.
Reporting is not required, but it serves a public health function. Pattern recognition in adverse event and medication error reports has triggered regulatory action against compounding pharmacies before. If you are one of many patients receiving incorrectly labeled vials from the same pharmacy, your report may contribute to a pattern that prompts investigation. The FDA has significantly increased scrutiny of compounded semaglutide and tirzepatide in 2025 and 2026, and patient reports are part of the information base that informs that oversight.
When reporting, document as much as you can: pharmacy name and location, lot number, the concentration stated on the label, what concentration you believe you actually received (if different), the instructions provided, and the adverse events or dosing discrepancy you experienced. Photographs of your label are directly useful here.
Finally, a note on the emotional context of this issue. Many patients using compounded GLP-1 medications chose this route because brand-name medications were unaffordable, unavailable, or not covered by insurance. They are navigating a complex and often frustrating healthcare system to access medications that work for them. This guide is not an argument against compounded GLP-1s or an effort to discourage patients from using them. It is an argument for patients having the information they need to use them safely. The math is straightforward, the verification steps are manageable, and the protection they provide is real.
Frequently Asked QuestionsFrequently Asked Questions
Why does my compounded GLP-1 label show units instead of milligrams?
Compounded GLP-1 medications are typically administered by subcutaneous injection using insulin syringes, which measure volume in units rather than milliliters or milligrams. A U-100 insulin syringe — the standard type in the United States — marks 100 units as equal to 1 milliliter. The syringe measures the volume of solution you draw; the dose in milligrams depends on both that volume and the concentration of the drug in the solution. Because compounding pharmacies set their own concentrations, the number of units required to deliver any given milligram dose varies by pharmacy and by batch. If your label shows unit instructions without also stating the resulting milligram dose, you should confirm both with your pharmacy.
How do I convert units to milligrams for my compounded semaglutide?
The formula is: units drawn divided by 100, then multiplied by the concentration in mg/ml, equals your dose in milligrams. For a 5 mg/ml concentration, drawing 5 units delivers 0.25 mg: (5 ÷ 100) × 5 = 0.25 mg. For a 7.5 mg/ml concentration, drawing 5 units delivers 0.375 mg: (5 ÷ 100) × 7.5 = 0.375 mg. If the concentration changes between batches and your unit instruction does not change, your dose in milligrams changes. To calculate the units needed to deliver a specific milligram dose, divide the prescribed dose in mg by the concentration in mg/ml, then multiply by 100. Run this calculation for every new vial.
My pharmacy changed the concentration of my compounded GLP-1. What do I need to do?
You need to recalculate your unit draw before your next injection. Contact your pharmacy and confirm the new concentration in mg/ml. Then apply the formula: (prescribed dose in mg ÷ new concentration in mg/ml) × 100 = units to draw. Confirm this calculation with your pharmacy — ask them to tell you explicitly how many units delivers your prescribed dose from the new concentration. Do not assume your previous unit instruction is still correct. If the pharmacy increased the concentration and your previous unit instruction stays the same, you will be over-dosed. If the concentration decreased and your instruction stays the same, you will be under-dosed. Either scenario should be corrected before you inject.
What are the risks of unknowingly taking the wrong dose of compounded semaglutide?
The risks depend on the direction of the error. An unintended dose reduction typically causes loss of medication effectiveness: reduced appetite suppression, a plateau in weight loss, or a return of symptoms the medication was managing. This is frustrating and medically suboptimal but is generally not acutely dangerous. An unintended dose increase carries more immediate concern: intensified nausea, vomiting, and diarrhea; potential dehydration; and in more severe cases, the full spectrum of GLP-1 adverse effects at higher-than-appropriate intensity. If you experience sudden worsening of GLP-1 side effects after starting a new vial, a concentration increase may be the cause. Contact your provider before your next dose, and do not continue from a vial you cannot verify.
Does the same concentration issue apply to compounded tirzepatide?
Yes. The same unit-to-milligram conversion math applies to any compounded injectable GLP-1 or GIP/GLP-1 medication, including compounded tirzepatide. Tirzepatide vials also carry a concentration in mg/ml, and drawing a fixed number of units delivers a milligram dose that depends on that concentration. Common compounded tirzepatide concentrations include 5 mg/ml, 10 mg/ml, and others depending on the pharmacy and prescribed dose. If your pharmacy changes the tirzepatide concentration between batches and does not update your instructions, you face the same under-dose or over-dose risk as with semaglutide. The verification steps described in this guide apply equally to both drugs.
How do I know if my compounding pharmacy is reputable and reliable?
Several indicators suggest a reputable compounding pharmacy for GLP-1 medications. First, the pharmacy should be licensed in the state where it operates and, if shipping across state lines, in the states where it ships. PCAB (Pharmacy Compounding Accreditation Board) accreditation is a voluntary quality credential worth looking for. Second, the pharmacy should label its products completely: drug name, concentration in mg/ml, total volume, lot number, beyond-use date, and pharmacy contact information. Third, the pharmacy should answer direct questions about concentration and dosing clearly and in writing. Fourth, the pharmacy should notify you proactively when formulation changes affect your dosing instructions. Pharmacies that cannot or will not provide complete labeling information, answer concentration questions, or communicate formulation changes are not meeting basic standards for patient safety, regardless of whether they meet the technical minimum for their license category.